Veränderung des Genoms basieren auf der Verwendung von artifiziellen Enzymen, so genannten „Designer-Nukleasen“. Hierzu zählen Zink-Finger Nukleasen ( ZFNs ), „Transcription activator-like effector“-Nukleasen [...] Reporterzelllinien, die in einem solchen Hochdurchsatzscreening Verwendung finden sollen, sind Designernukleasen ein wertvolles Werkzeug. So können vor allem transgene Reporterkonstrukte, welche ein autom [...] Während patientenspezifische iPS-Zellen bereits hergestellt, charakterisiert und mit Hilfe der Designernukleasen genetisch modifiziert bzw. korrigiert werden konnten, und auch die anschließende Differenzierung
patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design. eClinicalMedicine Vol. 65. DOI: 10.1016/j.eclinm.2023.102260 Krüger K, Lapstich AM, Reber KC, Sehlen [...] Stahmeyer JT, Krauth C (2023). Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle in [...] Krauth C (2021). How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in
L. L., Nolte, O., Sträter, N., Alber, G. & Hoffmann, R. ( 2012 ). Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chem [...] [1] Knappe, D., Zahn, M. , Sauer, U., Schiffer, G., Sträter, N. & Hoffmann, R. ( 2011 ). Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the
Participants in the 5th Cochrane Rehabilitation Methodological Meeting (incl. Gutenbrunner C). Designing studies and reviews to produce informative, trustworthy evidence about complex interventions in [...] Methodological Meeting Participants (incl. Gutenbrunner C). The role of single case experimental designs in evidence creation in rehabilitation. Eur J Phys Rehabil Med 2024; DOI: https://doi.org/10.237
Reaktogenität und Immunogenität von CVnCoV bei verschiedenen Dosierungen mithilfe eines adaptiven Dosisfindungsdesigns systematisch untersucht. Dies ermöglicht eine Dosissteigerung unter Verwendung vordefinierter
found their way into clinical application. In contrast to these effector CAR T cells, which are designed to kill tumour cells, we primarily deal with mechanisms of immune tolerance. In particular, regulatory
Krankheiten, prä-klinischer Sicherheit, Wirksamkeitsmodellen (inkl. Monitoring und Imaging) sowie dem Design und der Anwendung einer passenden Zell- und/ oder Vektorproduktion (inkl. Genom Editierung). Erfolgreiche
n and therapy 12:45-13:30 LUNCH BREAK 13:30-14:30 3R-concept and alternative methods 14:30-15:30 Design and planning of animal experiments 15:30-16:00 Introduction to Q-Exam (exam preparation) Subject
Trials with an Adaptive Design.” Biometrical Journal 48(4):574–85. Koch, Armin . 2005. “Discussion on ‘establishing Efficacy of a New Experimental Treatment in the “gold Standard” Design.’” Biometrical Journal [...] 2017. “Critical Appraisal of Arguments for the Delayed-Start Design Proposed as Alternative to the Parallel-Group Randomized Clinical Trial Design in the Field of Rare Disease.” Orphanet Journal of Rare Diseases [...] of Clinical Study Design”, RAPS Convergence, hybrid meeting – Long Beach (USA), Full Schedule 09/2023: "Estimand framework (regulatory perspective)" in Session "Innovative trial designs and estimands", CDDF
dependent on optimal instrument setup and meticulous panel design. Join us for this free seminar where we will delve into the setup and panel design of your BD FACSymphony™ A5 SE flow cytometer or other spectral [...] mh-hannover.de Free Flow Cytometry Workshop 14.01.2025 (Hörsaal N Gebäude J01-H0-1120) Advanced Panel Design and Instrument Setup for Optimal Marker Resolution and Sensitivity As we incorporate more parameters